این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Heart Journal، جلد ۲۳، شماره ۱، صفحات ۶-۱۶
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Comparison Between Intracoronary and Intravenous Eptifibatide and Intracoronary Reteplase in Patients Undergoing Primary Percutaneous Coronary Intervention: A Randomized Clinical Trial
چکیده انگلیسی مقاله Background: Despite the benefits of primary percutaneous coronary intervention (PPCI), myocardial perfusion after treatment remains disrupted in some patients. The utility of glycoprotein IIb/IIIa inhibitors and reteplase during the intervention is indeterminate.
Methods: We designed a randomized clinical trial to compare intravenous (IV) and intracoronary (IC) eptifibatide and reteplase in 144 patients with ST-elevation myocardial infarction scheduled for PPCI. The primary outcome was coronary blood flow according to the TIMI flow grade (TFG) before and after PPCI. The secondary outcomes were the differences between ST-segment resolution, diastolic left ventricular dysfunction, left ventricular ejection fraction, mitral regurgitation, CK-MB levels, and hemoglobin levels before and after PPCI.
Results: TFG III was achieved in all patients (100%) in the control and reteplase groups. TFG III was seen in 32 (88.9%) and 33 (91.7%) patients in the IV and IC eptifibatide groups, respectively. TFG II was reported in 4 (11.1%) and 3 (8.3%) patients in the IV and IC eptifibatide groups in the same order. Postprocedural TFG was not significantly different between the groups. There was a significant increase in the CK-MB level in the reteplase group compared with the other groups (P<0.05). Postprocedural hemoglobin, ST resolution, and ejection fraction were not significantly different between the groups. Reteplase was associated with a significant improvement in diastolic left ventricular dysfunction compared with the control group (odds ratio, 0.31; P=0.02). No difference was shown in the development of mitral regurgitation between the 4 groups.
Conclusions: Neither IV nor IC eptifibatide nor reteplase was associated with improvements in the coronary blood flow as determined by TFG, ST resolution, and ejection fraction. (Iranian Heart Journal 2022; 23(1): 6-16)
کلیدواژه‌های انگلیسی مقاله Primary percutaneous coronary intervention,Eptifibatide,Reteplase,intravenous,Intracoronary
نویسندگان مقاله Salman Nikfarjam |
Cardiovascular Disease Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran.

Mostafa Zadkamali |
Cardiovascular Disease Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran.

Arsalan Salari |
Cardiovascular Disease Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran.

Maryam Shakiba |
Cardiovascular Disease Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran.

Mahboubeh Janesar Hoseinie |
Cardiovascular Disease Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran.

Fardin Mirbolouk |
Cardiovascular Disease Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, IR Iran.

نشانی اینترنتی http://journal.iha.org.ir/article_142593_ac1215a7b2182f946aea83bd367edf60.pdf
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات